On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research ...

Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal ® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of ...

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Camurus delivered exceptional financial results in Q1 2025, with total revenue reaching SEK 558 million, representing a 43% increase year-over-year. The company achieved record-high profitability with ...

Camurus AB will release earnings for the most recent quarter on May 12. Analysts are expecting losses per share of SEK 0.219. Go here to follow Camurus AB stock price in real-time ahead of earnings.

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research ...

Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.